EUROPCAR/TAXEO
Regulatory News:
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160622006054/en/
Whether renting a car or booking a hotel, travelling for business in Europe incurs VAT costs. Europcar (Paris:EUCAR) he leading car rental provider in Europe and a major mobility player, and Taxeo, the leading provider of paperless VAT refund services, have entered into a partnership so their mutual clients are able to reclaim VAT quickly and easily according to local legislation.
The unique innovation developed by Taxeo is to receive electronic invoice data from Europcar and create tax-compliant electronic invoices that are used for VAT recovery.
Thanks to this partnership, Europcar Corporate customers are set to make significant savings.
Jean Cazes, CEO of Taxeo, called it a “milestone” in VAT recovery for business travel expenses. “This means that we are able to reduce car hire costs for our mutual clients by up to 15%. Our solution is very simple for companies and travellers to use. Moreover, it brings the additional benefit of tax-compliant e-invoices and structured data for expense management ” Cazes added.
Marcus Bernhardt, Chief Commercial Officer of the Europcar Group, also sees the partnership with the French company as a “wonderful opportunity” for the business: “This meets the price-sensitivity of our corporate clients and boosts our competitiveness and differentiation without impacting our revenues and commitment to service .”
Every year companies lose out on €5 billion VAT incurred on international travel. Today’s manual paper-based VAT recovery process, especially for travel expenses like hotel, car rental, conferences, etc., is complex, expensive, and inefficient, due mainly to non-compliant or lost invoices. The Taxeo solution addresses these issues. What’s more, a majority of small and medium-sized enterprises (SMEs) are often unaware that VAT can be refunded for business trips or how to apply for refund.
About Europcar Group:
Europcar shares (EUCAR) are
listed on the Euronext Paris stock exchange. Europcar is the European
leader in vehicle rental service and is also a major player in mobility
markets. Active in more than 140 countries, Europcar serves customers
through an extensive vehicle rental network comprised of its
wholly-owned subsidiaries as well as sites operated by franchisees and
partners. In addition to the Europcar® brand, the company offers
low-cost vehicle rentals under the InterRent® brand. A commitment to
customer satisfaction drives the company and its 6,000 people forward
and provides the impetus for continuous development of new services.
The Europcar Lab was created to respond to tomorrow’s mobility
challenges through innovation and strategic investments, such as Ubeeqo
and E-Car Club.
About Taxeo:
Taxeo is a FinTech startup, which has
developed the first paperless and fully automated VAT reclaim solution
for international European business travel.
Taxeo helps many
European and US based companies to recover VAT on travel related
expenses and supplier invoices.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160622006054/en/
Contact:
Media Contacts
EUROPCAR
Europcar
Press Office,
Tel: + 33 1 30 44 98 82
europcarpressoffice@europcar.com
or
Havas
Paris
Tel. +33 1 58 47 95 39
jean-baptiste.froville@havasww.com
or
Taxeo
Nils
Kernchen / Ama Lorenz
Tel: +33 1 43 87 71 14
n.kernchen@taxeo.com
press@taxeo.com
www.taxeo.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom